Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Merck & Co., Inc
Femme et Homme Max 99 ans
Merck & Co., Inc
MAJ Il y a 5 ans
A Phase IIa Randomized, Double-Blind, Parallel-Groups, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK-0724 Intravenous Infusion on the Amelioration of Neurological Damage and Recovery from Middle Cerebral Artery Ischemic Stroke
To compare the efficacy MK-0724 8 mg/kg/hr x 1 hr daily for 7 days to placebo in patients with middle cerebral artery ischemic stroke using the Day 90 Action Research Arm Test (ARAT) scores.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck & Co., Inc
MAJ Il y a 5 ans
A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety of MK-0431 Monotherapy in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency Who Have Inadequate Glycemic Control
In patients with type 2 diabetes mellitus and chronic renal insufficiency with inadequate glycemic control Primary: To assess the safety and tolerability of MK-0431 after 12 weeks.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Homme Max 99 ans
Merck & Co., Inc
MAJ Il y a 5 ans
A Phase III Study to Assess the Safety, Tolerability, and Efficacy of MK-0822 (Odanacatib) in Prolonging Bone Metastasis-Free Survival in Men with Castration-Resistant Prostate Cancer
• To assess the effect of treatment with MK-0822 5 mg once daily on bone metastasis-free survival (defined as time to first bone metastasis or death from any cause) compared to placebo. • To assess th...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
Merck & Co., Inc
MAJ Il y a 5 ans
A Phase III Study to Assess the Tolerability and Efficacy of MK-0822 (Odanacatib) in Reducing the Risk of Bone Metastases and Prolonging Disease-Free Survival in Women with Breast Cancer
Objective: To assess the effect of treatment with MK-0822 5 mg once daily on the risk of developing a first bone metastasis (first disease recurrence) compared to placebo Objective: To assess the ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme Max 99 ans
Merck & Co., Inc
MAJ Il y a 5 ans
A Phase II Study to Assess the Safety, Tolerability, and Efficacy of MK-0822 (Cathepsin-K Inhibitor) in the Treatment of Women with Breast Cancer and Established Bone Metastases (MBD)
E.2.1 Main objective: To assess the safety, tolerability, and biochemical efficacy (changes in urinary NTx) of MK-0822 in women with breast cancer and MBD
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
The effect and long-term safety of MK-0887A in children with asthma
Primary Efficacy Objective: To demonstrate the efficacy of MF/F 100/10 mcg twice daily, compared with MF 100 mcg twice daily, by evaluating lung function during the first 12 weeks of double-blind tre...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., N.J., USA
MAJ Il y a 5 ans
A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients with Cardiovascular Disease and Diabetes Mellitus Not Adequately Controlled with Simvastatin 20 mg or Atorvastatin 10 mg: A Comparison of Switching to a Combination Tablet Ezetimibe/Simvastatin (10mg/20mg) Versus Switching to Rosuvastatin 10mg or Doubling the Statin Dose
In patients with cardiovascular disease (CVD) and diabetes mellitus treated with simvastatin 20 mg or atorvastatin 10 mg with LDL-Cholesterol blood level (LDL-C) ≥70 mg/dl (1.81 mmol/L) and ≤160 mg/dl...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
Vaginal ring dose-finding study on ovarian function and vaginal bleeding in healthy women aged 18-35 years
1. Inhibition of ovulation, which is considered confirmed if in the subset of subjects for whom the test will be performed, ovulation is observed in less than 15% of the subjects at any time during th...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Merck & Co., Inc
MAJ Il y a 5 ans
A Phase III Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Prospectively Evaluate Efficacy of Montelukast in Patients Aged 6 Months to 5 Years With Chronic Asthma
E.2.1 Main objective: To demonstrate that montelukast, compared with placebo, improves asthma control (as measured by the percentage of days without asthma ) over a 24-week treatment period in patien...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 5 ans
Pembrolizumab (MK-3475) in High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Patients Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy
Objective 1: To evaluate anti-tumor activity of pembrolizumab (MK-3475), with regards to absence of high risk NMIBC or progressive disease, as determined by cystoscopy, cytology, biopsy (if applicable...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Précédent
9
10
11
12
13
14
15
16
17
18
Suivant